PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Fabrice Jollant

School of Medicine, Paris-Saclay University, Paul-Brousse Hospital, AP-HP, le Kremlin-Bicêtre, Villejuif, France; Department of Psychiatry, McGill University, McGill Group for Suicide Studies, Montreal, QC, Canada.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · JOURNAL ARTICLE

Intravenous Ketamine reduces psychological pain in suicidal inpatients: A secondary analysis of a six-week randomized placebo-controlled trial.

Journal of Affective Disorders

A double-blind RCT with adequate sample size and pre-specified primary endpoint shows ketamine reduces psychological pain acutely in suicidal inpatients, but effects do not persist beyond 96 hours and the clinical significance of this surrogate outcome remains unclear.

PromisingChristophe Demattei Bipolar Disorder Fabrice Jollant

Reported

Sample size: ketamine arm73

Sample size: placebo arm83

Ketamine dose0.5 mg/kg

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support